Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

CAPS Rating: 3 out of 5

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.


Player Avatar mfgd (77.24) Submitted: 4/28/2011 10:25:46 AM : Outperform Start Price: $27.75 VRTX Score: +28.26

Vertex (VRTX) shares have been halted as an FDA advisory panel will review its telaprevir NDA today
7:05 am ET 04/28/2011-

Sounds like GOOD NEWS!

Member Avatar mfgd (77.24) Submitted: 4/28/2011 4:24:29 PM
Recs: 0

-- A Food and Drug Administration advisory panel unanimously recommended approval of Vertex Pharmaceuticals'(VRTX_) proposed hepatitis C drug on Thursday.
More on VRTX
Vertex: FDA Hep C Panel Live BlogTrading Of Vertex Common Stock Halted TodayMerck: FDA Hep C Panel Live BlogMarket Activity
Vertex Pharmaceuticals| VRTX UPThe Antiviral Drugs Advisory Committee voted 18-0 to recommend the FDA give a thumbs-up to Vertex's new drug application for telaprevir

Trading will resume tomorrow.

Featured Broker Partners